SELDI

NEW YORK (GenomeWeb News) – Vermillion today announced that all four non-contingent contract claims with Bio-Rad Laboratories stemming from Vermillion's sale of its proteomics business

ProteoMonitor spoke to Cristobal Belda-Iniesta, head of the Biomarkers and Experimental Therapeutics for Cancer Group at Madrid's University Hospital La Paz, about his work applying proteomics to guide cancer therapy.

The patent's claims cover biomarker combinations for the diagnosis and management of Alzheimer's disease and their measurement by methods including mass spectrometry and immunoassay.

The system, called Lucid Proteomics, combining Bio-Rad's SELDI-based array technology with Bruker's ultrafleXtreme MALDI-TOF/TOF instrument, is expected to hit the market in late summer or early fall, and is the first fruit of a co-marketing and co-development collaboration between the two firms announced a month ago.

The company remains in business and continues work to get FDA approval for its ovarian tumor triage diagnostic. In its filing, the company said it had assets of about $7.2 million and liabilities of approximately $32 million as of Sept. 30, 2008.

In a competitive field where deals linking two mass-spec technologies from different vendors are unusual, the partnership could help Bio-Rad make relevant a technology that has failed to capture the interest of the research community.

Researchers describe a way to share data while keeping it secure, Agence France Presse reports.

In Science this week: genetic mutations typically associated with esophageal cancer are common in older, healthy individuals, and more.

India's Council of Scientific and Industrial Research has a new director-general, according to ScienceInsider.

A new study links more than a hundred genes to autism spectrum disorder, Discover's D-brief blog reports.